NCT07351136Not yet recruiting
Novel Diagnostic and Prognostic Predictors in Fabry Cardiomyopathy: Proof of Concept in a Rare Disease
Source: ClinicalTrials.gov · Last updated 20 Jan 2026
Brief summary (registry, in English)
In this work, we address the understanding of the signaling pathways involved in cardiac remodeling in human SCD through molecular imaging analysis with a fibrosis marker. Furthermore, we emphasize characterizing the cardiac remodeling process by analyzing proteomic data from SCD myocardial biopsies and by analyzing the profile of microRNAs associated with hypertrophic cardiomyopathy and their diagnostic and prognostic value.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 9 Jan 2026
- Start date
- 1 Jan 2026
- Primary completion date
- 31 Jan 2026
- Lead sponsor
- Núcleo de Apoio à Investigação Clínica - FMUP
- Diseases
- Fabry disease
- NCT number
- NCT07351136
What you commit to
- Study type: Observational
- Planned participants: 20
- From 1 Jan 2026 to the primary completion date, 31 Jan 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Refusal to participate in the study
Who the study is looking for
- Adult patients, over 18 years of age;
- Diagnosis of Fabry disease
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.